Company: Asklepios BioPharmaceutical
Job title: Vice President Translational Medicine
David Favre is Vice President of Translational Medicine at Asklepios BioPharmaceutical (AskBio), USA, bringing over 20 years of experience in immuno-virology and drug development in academic, biotech and industry settings. At AskBio, he leads the platforms and resources to marshal preclinical and early clinical programs, particularly focusing on the immunology of AAV re-dosing. In his previous position as director at GlaxoSmithKline and adjunct professor at the University North Carolina, Chapel Hill, David led over 10 new drug development programs in HIV immunotherapy and cure, encompassing small molecules and biologics targeting epigenetic, pattern recognition receptors, checkpoint inhibitors, redirected T-cell therapy and immuno-regulatory pathways. He established a strong network of internal and external collaborations in immune-oncology, innate immunity, host defense and immune-inflammation. Prior to GSK, David led the scientific innovation at ImmuneCarta-Caprion Biosciences, Montreal, for the immune monitoring and immunogenicity of small molecule drugs, biologics and vaccines in inflammatory diseases, infections and cancer conditions in biotech- and pharma-sponsored clinical trials. David hold a DVM from the veterinary school of Nantes, France and a PhD in Microbiology from the University of Paris. His PhD focused on AAV gene therapy and preclinical assessment of regulated gene expression in non-human primates at INSERM, Nantes and the Pasteur Institute, Paris, and his post-doctoral fellowship was on the immunology and immunopathology of HIV disease at the Gladstone Institute and UCSF, San Francisco.
Immunogenicity of Novel AAV Vectors 2:50 pm
• Understanding adaptive and innate immunity to AAVs through preclinical models and clinical assessment strategies • Developing inclusion and exclusion criteria and utilizing in-life monitoring • What does pre-existing immunity mean for re-dosing and what are the safety considerations?Read more
day: Day Two
Live Q&A – Ask the speakers your questions 3:50 pm
day: Day Two